Novartis, CH0012005267

Novartis stock trades at EUR 128.57 with volume 3.2 percent below average

Published on 10/12/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock trades at EUR 128.57 on October 12, 2026. The bid is EUR 128.54 and the ask is EUR 128.60 for the quote.

Key points in brief

Novartis stock was trading at EUR 128.57 at Lang & Schwarz on October 12, 2026 at 1:37 p.m. CEST.
Quote volume was 3.20 percent below the reported average of 1,963,846 shares on October 9, 2026.
MarketBeat reported a Hold consensus from 20 firms and an average USD 145.60 12-month target on October 7, 2026.
Novartis is scheduled to report third-quarter 2026 results on October 27, 2026.

Isometrische Low-Poly-Illustration eines Pharmalabors mit Robotern und Inkubatoren — Novartis AG CH0012005267 – Isometrisches Low-Poly-Labor mit Robotern, Inkubatoren und vielen Wissenschaftlern, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) was trading at EUR 128.57 at Lang & Schwarz on October 12, 2026 at 1:37 p.m. CEST. The bid was EUR 128.54 and the ask was EUR 128.60, placing the quote in a narrow EUR 0.06 spread for investors following the Swiss pharmaceutical group.

Volume stays below its average

Quote volume stood at 1,900,903 shares on October 9, 2026, compared with an average of 1,963,846 shares. That is 3.20 percent below the average, a market participation measure that gives the price move less confirmation than a session with heavier turnover.

The latest finance snapshot also put Novartis market capitalization at USD 273.2 billion and the price-to-earnings ratio at 21.95 on October 9, 2026. Those figures describe the U.S.-dollar quotation context and are separate from the euro quote at Lang & Schwarz.

Analysts keep a Hold consensus

MarketBeat reported on October 7, 2026 that 20 firms held a consensus rating of Hold, with 12 hold, six buy and two sell ratings. The average 12-month target was USD 145.60, while Morgan Stanley carried a USD 156.00 target and Berenberg had lowered its target from USD 147.00 to USD 130.00 on September 11, 2026.

For the Swiss listing, 6ix identifies Novartis as NOVN on SIX Swiss Exchange and classifies it in pharmaceuticals. This listing context matters because the analyst targets above are expressed in U.S. dollars, while the German investor quote is expressed in euros.

Results date is set

Novartis lists October 27, 2026 as the date for its third-quarter 2026 financial results on its investor calendar. The date gives the market a defined point for reassessing sales, earnings and the company outlook.

Price and market context

The Lang & Schwarz quote was EUR 128.57 on October 12, 2026 at 1:37 p.m. CEST. The quote remains separate from the U.S.-dollar market capitalization and analyst targets, so cross-currency comparisons are not used.